Octant Doses First Patient in Phase 1b/2 OCT-980 Study
EMERYVILLE, Calif. — September 24, 2026 Octant, Inc. announced that the first patient has been dosed in the Phase...
Age-related Macular Degeneration
Advertisement
Annexon to Present Vonaprument Data From ARCHER II
BRISBANE, Calif. — September 24, 2026 Annexon, Inc. announced that it will present two oral presentations on vonaprument at...
Telomir Publishes Telomir-Zn AMD Preclinical Findings
MIAMI, Fla. — September 17, 2026 Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn...
Ocular Therapeutix Advances AXPAXLI Toward Wet AMD NDA
BEDFORD, Mass. — September 15, 2026 Ocular Therapeutix, Inc. announced the successful completion of its Pre-New Drug Application (Pre-NDA)...
Eyconis, Inc. Begins First-in-Human EYC-0305 Trial in Wet AMD
REDWOOD CITY, Calif., August 18, 2026 Eyconis, Inc. announced the initiation of OVERTURE, its first-in-human Phase 1b/2a clinical trial...
Advertisements
Outlook Therapeutics Targets U.S. Launch of FDA-Approved LYTENAVA
ISELIN, N.J., August 14, 2026 Outlook Therapeutics, Inc. is advancing preparations for the U.S. commercial launch of LYTENAVA™ (bevacizumab-vikg)...
Samsung Biologics to Acquire PolyPeptide for CHF 1.46B
INCHEON, South Korea, July 20, 2026 Samsung Biologics has announced a landmark all-cash public tender offer to acquire 100%...
SystImmune Advances Oncology Portfolio with Iza-bren Approval
REDMOND, Wash., July 17, 2026 SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., has received...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150
EMERYVILLE, Calif., July 18, 2026 4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical...
Advertisement
